Drugs that have reached the bottom IVE viral suppression, were lower in patients with active agent. These percentages are comparable to those with two active drugs Histamine Receptor in clinical trials combined with background lopinavir and ritonavir treated 21 and 18, but maraviroc are lower than those of patients with raltegravir, etravirine, 13, 19 or treated in arm darunavir.21 TRIO only ANRS, 22 86% of patients had HIV RNA below 50 copies per mL at week 48, although these people u Three new drugs have a base salary plus again. High proportions of voluntary waivers say, by withdrawal of consent, loss aff ected adherenceor not to track response rates in our study, especially in the subgroup of patients with two drugs active background. In the DUET studies, 19 51 given up to 1203 people at week 48, but in our study, 105 of 702 patients who were 48 weeks and sold as failures.
The high proportion of dropouts in our study was accompanied by low adhesion measured by the number of tablets. Write-fa If a volunteer is more significant tilting in patients with both active ingredients in the substance of which a single drug active background. If patients in our study for the treatment AT9283 of her broken Remained until week 48 Feeder Llig scored three quarters of those affected elvitegravir viral suppression, highlighting the eff ect of voluntary waivers of e modified intention to treat response rates. Our study suggests a Ver Change in the type of treatment experienced patients in clinical trials for HIV. In previous studies, people with limited Behandlungsm Were possibilities and therefore the motivation enrolled adhere to treatment.
In our study we found that dropouts fa More significant is a volunteer cant arises in patients with two active drugs as background in a single active drug background. Moreover, had only a quarter of patients who were tested in our study, resistance mutations of integrase by two thirds in these cases Chern BENCHMRK studies.13 In addition to our study, 23 of the 119 patients tested two drugs with active background to 13 September with an active drug showed resistance mutations compared to integrase. Since raltegravir or elvitegravir must be present in the plasma of select integrase resistance, this indicates significant difference ENCE cant that patients with treatment options, which had less virological failure Anh singer to study drugs than were those with fewer opportunities Behandlungsm.
In future experiments should be considered cation stratification by the number of active background drugs. Clinical trials of drugs for diseases other than HIV infection nnte k Aff ected than his treatment options increase by one Similar Ver Change in the behavior of patients. Each individual in our study was to actively raltegravir twice t Possible or placebo and elvitegravir, so that the receiver gave singer a are daily dose of elvitegravir t was not evaluated. However, since the non-inferiority of raltegravir in patients showed, eh Fs antiretroviral treatment could be added to an investigational ritonavir boosted protease inhibitor and NRTI single or a combination to create a regime once per day. Studies of elvitegravir as part of a single dose in patients well Fs treatment